Reevaluation of the Frequent Use of PD-1 Checkpoint Inhibitors for Treatment of Glioblastoma

JAMA. 2020 Jun 23;323(24):2482-2484. doi: 10.1001/jama.2020.5934.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • B7-H1 Antigen
  • Brain Neoplasms*
  • Glioblastoma*
  • Humans
  • Immunologic Factors
  • Programmed Cell Death 1 Receptor

Substances

  • B7-H1 Antigen
  • Immunologic Factors
  • Programmed Cell Death 1 Receptor